ORIGINAL ARTICLE

Chondrogenesis of periodontal ligament stem cells by transforming growth factor-β3 and bone morphogenetic protein-6 in a normal healthy impacted third molar

Sunyoung Choi1,2*, Tae-Jun Cho1,2*, Soon-Keun Kwon1,2, Gene Lee2,3 and Jaejin Cho1,2

The periodontal ligament-derived mesenchymal stem cell is regarded as a source of adult stem cells due to its multipotency. However, the proof of chondrogenic potential of the cells is scarce. Therefore, we investigated the chondrogenic differentiation capacity of periodontal ligament derived mesenchymal stem cells induced by transforming growth factor (TGF)-β3 and bone morphogenetic protein (BMP)-6. After isolation of periodontal ligament stem cells (PDLSCs) from human periodontal ligament, the cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 20% fetal bovine serum (FBS). A mechanical force initiated chondrogenic differentiation of the cells. For chondrogenic differentiation, 10 μg L−1 TGF-β3 or 100 μg L−1 BMP-6 and the combination treating group for synergistic effect of the growth factors. We analyzed the PDLSCs by fluorescence-activated cell sorting and chondrogenesis were evaluated by glycosaminoglycans assay, histology, immunohistochemistry and genetic analysis. PDLSCs showed mesenchymal stem cell properties proved by FACS analysis. Glycosaminoglycans contents were increased 217% by TGF-β3 and 220% by BMP-6. The synergetic effect of TGF-β3 and BMP-6 were shown up to 281% compared to control. The combination treatment increased Sox9, aggrecan and collagen II expression compared with not only controls, but also TGF-β3 or BMP-6 single treatment dramatically. The histological analysis also indicated the chondrogenic differentiation of PDLSCs in our conditions. The results of the present study demonstrate the potential of the dental stem cell as a valuable cell source for chondrogenesis, which may be applicable for regeneration of cartilage and bone fracture in the field of cell therapy.

International Journal of Oral Science (2013) 5, 7–13; doi:10.1038/ijos.2013.19; published online 12 April 2013

Keywords: bone morphogenetic protein-6; chondrogenesis growth factor; periodontal ligament cell; stem cell; transforming growth factor-β3

INTRODUCTION

Stem cells are undifferentiated, have the potential to proliferate without differentiation, and can change their identity in an organ specific manner.1 Adult tissues include not only fully differentiated and specialized cells, but also pluripotent cells, which function similarly to embryonic stem cells, and are called adult stem cells. These adult stem cells have been focused upon as a promising tool for understanding tissue development and regeneration.2 Stem cells are also present in dental tissues, including dental pulp, periapical follicles and periodontal ligaments.3 Periodontal ligaments (PDLs) are a specialized connective tissue, consisting mainly of collagen fibers that attach a tooth to the alveolar bone. The fibers help the tooth withstand the loading during chewing and remain embedded in the alveolar bone socket. PDLs also contain several cellular components such as fibroblasts, osteoblasts and cementoblasts.4 PDL-derived mesenchymal stem cells have the ability to regenerate periodontal tissues and pulp. A previous study reported that during the periodontal wound healing process, these cells migrated from the residual PDL to regenerate alveolar bone tissue.4

Recently, several studies reported the pluripotency of periodontal ligament cells.4–8 It was found that cells in the periodontal ligament express markers of bone marrow mesenchymal stem cells, which suggests that stem cells are present in the periodontal ligament.5–6 Under specialized conditions, these stem cells, called periodontal ligament stem cells (PDLSCs), differentiated into cementoblast-like cells and adipocyte-like cells, and even exhibited the capacity to generate a structure similar to cementum and PDL architecture when transplanted into immunocompromised rodents.5,6 Additionally, it was reported that these cells might have the potential to differentiate into chondrocyte-like cell types and express small amounts of collagen type II and glycosaminoglycans (GAG) in chondrogenesis-inducing cultures.7 Chondrogenesis of PDLSCs has also been attempted with demineralized dentin implanted into PDLs in vivo;8 however, the purpose of these trials was simply to demonstrate the multipotent ability of PDLSCs.

1Laboratory of Developmental Biology and Stem Cell Differentiation/Transplantation, Department of Dental Regenerative Biotechnology, School of Dentistry, Seoul National University, Seoul, Korea; 2Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Korea and 3Laboratory of Molecular Genetics, School of Dentistry, Seoul National University, Seoul, Korea
*These authors contributed equally to this work.
Correspondence: Dr J Cho, Laboratory of Developmental Biology and Stem Cell Differentiation/Transplantation, Department of Dental Regenerative Biotechnology, School of Dentistry, Seoul National University, 28 Yongun-dong, Chongne-gu, Seoul 110-730, Korea
E-mail: jcho@snu.ac.kr
Received 14 May 2012; accepted 14 January 2013
Chondrogenesis is defined as the process through which mesenchymal stem cells differentiate into chondroblasts that subsequently develop into either adult chondrocytes or undergo hypertrophy and apoptosis. Chondrogenesis of stem cells has been focused upon to complement the low self-repairing ability of natural articular cartilage. Unlike most natural tissues, articular cartilage has only a limited capacity for self-repair, and thus even minor damage can have detrimental effects. Specifically, it is the damage of the related articular cartilage that causes osteoarthritis, which is a very irritable and painful disease and substantially decreases quality of life. Until now, treatment of this disease focused on assuaging symptoms. Although numerous biological approaches for articular cartilage repair have been attempted, they are still experimental and their efficacy is questionable. However, replacement of damaged cartilage with new cartilage may be a solution to this condition. Indeed, cell therapy using chondrocytes or their precursors embedded in some biocompatible scaffold is a possible approach for cartilage reconstruction. Finding proper cells that can differentiate into chondrocytes, as well as identifying the conditions necessary for inducing chondrogenesis is a first step for the regeneration of articular cartilage. Furthermore, formation of artificial cartilage could be applied to plastic surgery of the nose or ears.

Thus, the aim of this study was to demonstrate the stem cell properties of PDLSCs by inducing chondrogenesis with the known chondrogenic growth factors transforming growth factor (TGF)-β and bone morphogenetic protein (BMP)-6 in order to contribute to a better understanding of the development of articular cartilage. Furthermore, the results suggest a potential step toward the formation of artificial cartilage.

**MATERIALS AND METHODS**

**Cell isolation and cell culture**
PDL-derived cells were obtained from the normal healthy impacted third molar of a patient at Seoul National University Dental Hospital; this protocol was approved by the Institutional Review Boards (IRB) of Seoul National University Medical Ethics Committee. After washing the tooth with fresh Hank’s balanced salt solution (GBICO, Grand Island, NY, USA), PDL tissue was separated from the surface of the tooth and digested in 1 g·L⁻¹ collagenase type I and 2.4 g·L⁻¹ dispase (GBICO, Grand Island, NY, USA) for 1 h at 37°C, followed by filtering through 100 μm mesh. The solution was then centrifuged at 400g for 4 min at 4°C and the resulting cell PDL-derived cell pellet was resuspended in Dulbecco’s modified Eagle’s medium (DMEM; Welgene, Daegu, Korea) containing 20% fetal bovine serum (FBS; HyClone Laboratories, Vancouver, Canada). The cells were cultured in DMEM solution containing 20% FBS (HyClone Laboratories, Vancouver, Canada) with 1% antibiotic-antimycotic solution at 37°C in a 5% CO₂ humidified atmosphere. Cells at the sixth passage were used for experiments.

**Chondrogenic differentiation**
To trigger chondrogenesis of PDLs, a mechanical force formed three-dimensional (3D) cell cluster was created using 250 000 PDLs per cluster by centrifugation at 500g for 5 min at 4°C. The PDL-derived 3D clusters were differentiated with TGF-β3 and BMP-6, which are known chondrogenic growth factors for mesenchymal stem cells derived from bone marrow and adipose tissue. Defined medium, which was optimized in our lab, consisted of 100 nmol·L⁻¹ dexamethasone, 50 mg·L⁻¹ ascorbate-2-phosphate, 100 mg·L⁻¹ sodium pyruvate, 40 mg·L⁻¹ L-proline and 1% ITS+Premix (all Sigma-Aldrich, St. Louis, MO, USA) based on high-glucose DMEM; this media served as a control. For chondrogenesis, the defined media was supplemented with either 10 μg·L⁻¹ TGF-β3 (R&D Systems, Minneapolis, MN, USA) or 100 μg·L⁻¹ BMP-6 (R&D Systems, Minneapolis, MN, USA). To evaluate the synergistic effects of both TGF-β3 and BMP-6 for chondrogenesis on human PDLSCs (hPDLSCs), a defined media containing both TGF-β3 and BMP was used. We maintained the chondrogenic differentiation process for 14 days.

**Fluorescence-activated cell sorting analysis**
For fluorescence-activated cell sorting (FACS) analysis, hPDLSCs were harvested on day 14 of culture after isolation and purification. The cells were washed with phosphate buffer solution (PBS) and then stained with the following antibodies: fluorescein isothiocyanate (FITC)-conjugated mouse anti-human CD14, CD31, CD44 and CD45; phycoerythrin (PE)-conjugated mouse anti-human CD29, CD73 and CD117; PE.Cy5-conjugated mouse anti-human CD90; antigen-presenting cell-conjugated mouse anti-human CD34 and HLA-DR; streptavidin-conjugated PE; biotin-conjugated HLA class I (all from BD, San Diego, CA, USA); and antigen-presenting cell-conjugated mouse anti-human CD105 (eBioscience, San Diego, CA, USA). Each primary antibody was incubated with 100 000 cells for 30 min on ice. After washing, the secondary antibody was applied for 30 min on ice and then cells were fixed with 4% paraformaldehyde at 4°C. The fluorescence intensity was measured with a FACSCalibur flow cytometer (BD, San Diego, CA, USA) and data were analyzed via FLOWJO software (Tree Star, Inc., San Carlos, CA, USA).

**Macroscopic analysis**
hPDLSC pellets were observed on day 14 using a stereoscopic microscope (SMZ645; Nikon, Tokyo, Japan) and photographs were taken with a microruler for size analysis.

**GAGs assay**
The level of sulfated GAGs in the hPDLSC pellets harvested on day 14 of culture was measured using a Blyscan Sulfate Glycosaminoglycan Assay (Biocolor Ltd, Belfast, Ireland) according to the manufacturer’s instructions. Pellets were digested in 1 ml Papain buffer (100 mL of 0.2 mol·L⁻¹ sodium phosphate buffer, 0.1 mol·L⁻¹ sodium acetate, 10 nmol·L⁻¹ ethylene diaminetetraacetin acid (EDTA), 5 mmol·L⁻¹ L-cysteine and HCl, pH 6.4) with 10 mg·L⁻¹ of papain for 24 h in a 60°C water bath, and then centrifuged at 3 300g for 5 min. Absorbance of the samples was measured with an enzyme-linked immunosorbent assay (ELISA) reader (S500; BIO-RAD, Hercules, CA, USA) at 656 nm and chondroitin-4-sulfate solution was used as a standard. Total cellular DNA content was measured using a pico-green dsDNA assay kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. The level of GAGs was normalized versus the total amount of DNA.

**Total RNA extraction and reverse transcription-polymerase chain reaction**
On day 14, total RNA was extracted from hPDLSC pellets using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and treated with DNase I (Roche, Mannheim, Germany) to remove possible DNA contaminants. The RNA was reverse-transcribed into complementary DNA by M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocols. The amount of cDNA was determined by PCR using AccuPower PCR PreMix (Bioneer, Daejeon, Korea) according to the manufacturer’s instructions. In this
way, the gene expression level of chondrogenic markers including collagen type I, II and X; SOX9, RUNX2; and aggrecan in the pellets was measured and normalized to their glyceraldehyde-3-phosphate dehydrogenase mRNA level (Table 1).

**Histological and immunohistochemical analysis**

Three-dimensional hPDLSC pellets harvested after 14 days of culture were embedded in paraffin and sectioned as 4-μm-thick slices. The paraffin sections were deparaffinized using Histo-clear II (Natural Diagnostics, Blackburg, VA, USA) and hydrated in alcohol. The specimens were stained with hematoxylin and eosin (Sigma-Aldrich, St. Louis, MO, USA) to identify and evaluate cell morphology. GAGs were visualized by staining with alcin blue (Wako, Osaka, Japan) and safranin-O/fast green (Fisher, Fair Lawn, NJ, USA).

Synthesized type I collagen in the pellets was detected by immunohistochemical staining using the ABC kit (Invitrogen, Camarillo, CA, USA), a secondary antibody, for 30 min. Type I collagen (Abcam, Cambridge, UK) as a primary antibody and anti-rabbit IgG (Invitrogen, Camarillo, CA USA), followed by diaminobenzidine (DAB kit; Invitrogen, Camarillo, CA, USA), was visualized. The same procedures were followed for staining of type II collagen, except monoclonal mouse anti-human type II collagen (Calbiochem, Darmstadt, Germany) as a primary antibody and anti-mouse IgG (Invitrogen, Camarillo, CA, USA) as a secondary antibody were used.

**Statistical analysis**

Four independent experiments were performed in triplicate and the data are presented as means±s.d. Data analysis was performed using Student’s t-test at a significance level of P<0.05.

**RESULTS**

**FACS analysis and macroscopic analysis**

For the characterization of hPDLSC properties, we analyzed stem cell surface markers by FACS. Mesenchymal stem cell markers were homogeneously expressed in the cells as follows: 99.73% CD29, 99.54% CD44, 97.55% CD73, 84.80% CD90 and 51.54% CD105. The hematopoietic and endothelial markers were expressed in a small number of cells as follows: 0.3% CD14, 0.17% CD31, 0.35% CD34, 0.16% CD45, 0.17% CD117 and 0.65% HLA-DR. These results are consistent with previously published data (Figure 1a).6,13–15 The size of the chondroclusters was measured with a stereoscopic microscope and a microruler. Although the chondroclusters were each treated in a different medium, they were similar in size, approximately 0.7 mm (Figure 1b).

**GAG assay**

The sulfated GAG contents of the pellets were measured after 14 days and normalized according to the total amount of cellular DNA. GAG synthesis was increased by 217% in cells treated with 10 μg·L⁻¹ TGF-β3 and by 220% in those treated with 100 μg·L⁻¹ BMP-6. The combination treatment of TGF-β3 and BMP-6 induced an even higher increase in GAG content (281%). Further, the medium containing both growth factors induced GAG synthesis 130% more than TGF-β3 alone and 128% more than BMP-6. The increases in GAG levels were all statistically significant (P<0.01). Total DNA levels, which reflected the viability and proliferation of cells in the four conditions, were similar, indicating that these results are reliable (Figure 2).

**Reverse transcription-polymerase chain reaction**

The expression of genetic markers related to chondrogenesis was measured by reverse transcription-polymerase chain reaction (RT-PCR). The genes assayed in this experiment were SOX9, aggrecan, collagen type II, collagen type X and RUNX2. hPDLSCs cultured in the defined media expressed all markers except collagen type X. Both TGF-β3 and BMP-6 increased the expression of SOX9, which is known as a critical chondrogenesis related transcription factor, by 1.46- and 2.71-fold, respectively, compared to the control treatment. Furthermore, combination treatment with TGF-β3 and BMP-6 increased the expression of SOX9 by 3.97-fold compared with the control treatment. Furthermore, the combination of both growth factors upregulated SOX9 expression compared to TGF-β3 alone by 2.71-fold and BMP-6 alone by 1.46-fold. Aggrecan expression was also increased in the presence of the growth factors compared to the control treatment as follows: 4.69-fold with TGF-β3, 7.50-fold with BMP-6 and 18.60-fold with both. The expression of collagen type II was increased considerably more than the other markers in the presence of the growth factors. Specifically, TGF-β3 increased collagen type II expression by 5.29-fold, BMP-6 by 4.63-fold and both by 23.15-fold compared with the control treatment. Lastly, with respect to increases...
Figure 1  FACS analysis and macroscopic sizing. (a) Immunophenotype characterization of PDLSCs at passage 6. Cells were homogeneously positive for mesenchymal stem cell markers (99.73% CD29, 99.54% CD44, 97.55% CD73, 84.80% CD90, 51.54% CD105) and negative for markers of hematopoietic stem cells or endothelial cells (0.3% CD14, 0.17% CD31, 0.35% CD34, 0.16% CD45, 0.17% CD117, 0.65% HLA-DR). (b) Picture of the chondro-balls cultured in four different kinds of chondrogenic media for 14 days. They were of similar size despite the different media compositions. D: control; T: 10 μg·L⁻¹ TGF-β3, B: 100 μg·L⁻¹ BMP-6; T+B: 10 μg·L⁻¹ TGF-β3 plus 100 μg·L⁻¹ BMP-6. FACS, fluorescence-activated cell sorting; PDLSC, periodontal ligaments stem cell; TGF, transforming growth factor; BMP, bone morphogenetic protein.

Figure 2  Differentiation ability of periodontal ligament derived cells into chondrocyte. (a) Relative amount of glycosaminoglycan/DNA content in each chondro-ball grown in the four different media types. GAG synthesis was increased by 217% in TGF-β3 containing media and by 220% in BMP-6 containing media. The presence of both TGF-β3 and BMP-6 increased GAG synthesis by 281%. (b) Total amount of DNA in each chondro-ball, indicating that the viability and proliferation of cells in the four conditions were similar, which implies that the results are reliable. D: control; T: 10 μg·L⁻¹ TGF-β3, B: 100 μg·L⁻¹ BMP-6; T+B: 10 μg·L⁻¹ TGF-β3 plus 100 μg·L⁻¹ BMP-6. GAG, glycosaminoglycan; TGF, transforming growth factor; BMP, bone morphogenetic protein.
Histological and immunohistochemical analysis

Hematoxylin and eosin staining showed that the cells cultured with BMP-6 were more spindle-shaped compared to others, and that cells grown in a cocktail of TGF-β3 and BMP-6 had larger nuclei and appeared to be arranged in two layers, namely, an inner layer and an outer layer. In the inner layer, the cells and nuclei appeared round; however, in the outer layer, the cells had a spindle shape. Alcian blue staining also showed a similar arrangement of the cells cultured in the cocktail. The nuclei of the cells were more prominent and round with safranin-O staining, while the layering pattern was clearly observed in the immunohistochemical staining for type I collagen. In the cells grown with both growth factors, the staining was much more intense in the chondro-balls grown with both growth factors, the staining was much more intense in the outer layer of the cell clusters compared to the inner layer. Type I collagens were evenly distributed in the extracellular matrix in cells cultured in the TGF-β3 and 100 μg·L⁻¹ BMP-6 medium. With respect to immunohistochemical staining for collagen type II, a pale brownish color was evenly distributed (Figure 4).

DISCUSSION

In this study, we demonstrated that human periodontal ligament-derived mesenchymal stem cells underwent chondrogenic induction upon treatment with growth factors, demonstrating sulfated glycosaminoglycan synthesis, expression of chondrogenesis-related genes, and increased chondrogenic protein abundance by immunohistochemistry. The growth factors TGF-β3 and BMP-6 not only induced
Periodontal ligament cell chondrogenesis
S Choi et al

Periodontal cell chondrogenesis on their own, but also showed a synergistic effect. The ability of TGF-β3 to enhance chondrogenic differentiation has been widely demonstrated and applied in various studies. BMP-6 induces chondrogenesis more efficiently than TGF-β3 in adult stem cells derived from adipose tissue. TGF-β3 and BMP-6 may promote very early events in chondrogenesis and directly or indirectly maintain their regulation during the differentiation and maturation of chondrocytes. Similar to other stem cells, PDLSCs underwent chondrogenesis more efficiently in the presence of both TGF-β3 and BMP-6. Even though there was no significant difference between the two growth factors in terms of induction, the combination of the growth factors stimulated increased chondrogenesis.

As shown in Figure 1a, the homogeneously high expression of CD29 (β1-integrin) and CD44 (hyaluronic acid receptor) indicated that the PDLSCs used in this study were mainly mesenchymal stem cells. CD90 (Thy-1) is a marker of various kinds of stem cells and specifically, it is a major marker of hematopoietic stem cells in combination with CD34. The CD90 positivity with the low level of CD34 expression demonstrated that there were few hematopoietic stem cells present in the isolated PDL cells. Further, the relatively low level of CD105 (endoglin), which is a specific marker for mesenchymal stem cells, implied the existence of an osteogenic differentiation process. Lastly, the low levels of CD14, a monocyte and macrophage marker, CD31, an endothelial cell marker, CD34, the hematopoietic early progenitor marker, CD45, the leukocyte common antigen, and CD117, a hematopoietic stem cell marker, demonstrated that the PDLSCs used in this study were not contaminated by hematopoietic stem cells or endothelial cells. In general, the cell surface marker expression of PDLsc showed similar expression as MSC. It means that the cells can be used as a strong stem cell source for cell therapy.

Chondrogenesis-related markers, SOX9, aggrecan, and collagen type II were all upregulated upon treatment with the growth factors. The first step in chondrogenesis is mesenchymal condensation mediated first by paracrine factors and subsequently by SOX9. Previous studies found that SOX9 is the clearest marker of chondrogenesis, as cells undergoing mesenchymal condensation begin to differentiate into chondrocytes. SOX9 is responsible for the expression of some of the key genes in chondrogenesis, namely SOX5, SOX6 and collagen II (Col2a1). It was previously reported that the expression of SOX9 is regulated by members of the TGF-β, bone morphogenetic protein (BMP), FGF and Wnt families. Thus, the increased expression of SOX9 in our results implies the stimulation of chondrogenesis. However, the expression of both collagen type X, a hypertrophy-related factor, and Runx2, an osteogenesis-related factor, were also increased.

The mesenchymal stem cell properties of the cultured PDLSCs were indicated by the homogeneously positive expression of several stem cell specific markers on the surface, including CD29 and CD44. Furthermore, homogeneously negative expression of CD14, CD31, CD34, CD45 and CD117 indicated that the cells were not contaminated by hematopoietic stem cells or endothelial cells.

The growth factors enhanced the synthesis of GAG while maintaining a constant level of cell proliferation and viability. Proteoglycans are the second-most abundant proteins in cartilage matrix, and chondroitin sulfate is the predominant glycosaminoglycan in cartilage. The combination of growth factors induced more GAG production, which confirmed their synergistic effect. This was also supported by the increased expression of chondrogenesis-related genes. In response to the growth factors, chondrogenesis-related genes, SOX9, aggrecan and collagen type X, were upregulated. The expression of aggrecan and collagen type II were considerably increased by the cocktail of the growth factors. Aggrecan, one of the substrates of chondroitin sulfate, is the most abundant proteoglycan in cartilage. Deposition of aggrecan has been considered a hallmark of chondrogenesis.

Immunohistochemical staining indicated synthesis of type I and type II collagens in the extracellular matrix. Cells cultured in BMP-6 medium appeared to be more spindle-shaped than others, and those grown in both TGB-β3 and BMP-6 seemed arranged in two distinct layers, namely, an inner layer and an outer layer. Most of the results suggest that the growth factors TGF-β3 and BMP-6 induced chondrogenesis in PDLSc; however, expression of several unexpected markers such as collagen type X and Runx2 were also stimulated by the growth factors. This limitation should be evaluated in further studies. PDLSCs showed a similar pattern of chondrogenic differentiation compared with other stem cells, expressing chondrogenesis-related genes and synthesizing extracellular matrix proteins successfully in the presence of growth factors.

Since PDLSCs are neural crest origin, known as a type of MSC, have a high proliferative and multipotent capacity. Extracted supernumerary or the third molar teeth, which was wastes of dental procedures, might be a valuable stem cell sources. In technically, getting bone marrow is aggressive, and needing general anesthesia but teeth can be easily obtained during dental treatment. In this reason, MSC from teeth, like PDLSc, can be banked for long period and used as a source of stem cell therapy for many diseases.

In summary, we investigated the stem cell properties of PDL cells by inducing chondrogenesis using growth factors, TGF-β3 and BMP-6. This work demonstrated the potential of dental stem cells as a valuable cell source for chondrogenesis, which can be applied to the regeneration of cartilage in the tissue engineering field. These results also confirm that PDLSCs can be used in tissue-engineering approaches for the treatment of osteoarthritis, temporomandibular joint disorder, and cartilage reconstruction.

ACKNOWLEDGEMENTS
This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MEST) (No. 860–20110087).

1. Blau HM, Brazelton TR, Weimann JM. The evolving concept of a stem cell: entity or function? Cell 2001; 105(7): 829–841.
2. Bosnakovski D, Mizuno M, Kim G et al. Chondrogenic differentiation of bone marrow mesenchymal stem cells (MSCs) in different hydrogels: Influence of collagen type II extracellular matrix on MSC chondrogenesis. Biotechnol Bioeng 2006; 93(6): 1152–1163.
3. Zhang W, Yelick PC. Vital pulp therapy-current progress of dental pulp regeneration. Int J Dent 2010; 2010: 856087. doi: 10.1155/2010/856087. Epub 2010 Apr 28.
4. Ohta S, Yamada S, Matuzaka K et al. The behavior of stem cells and progenitor cells in the periodontal ligament during wound healing as observed using immunohistochemical methods. J Periodontal Res 2008; 43(6): 595–603.
5. Seo BM, Miura M, Grontros S et al. Investigation of multipotential postnatal stem cells from human periodontal ligament. Lancet 2004; 364(9429): 149–155.
6. Nagatomo K, Komaki M, Sekiya I et al. Stem cell properties of human periodontal ligament cells. J Periodontal Res 2006; 41(4): 303–310.
7. Gay IC, Chen S, MacDougall M. Isolation and characterization of multipotent human periodontal ligament stem cells. Orthod Craniofac Res 2007; 10(3): 149–160.
8. Ma Z, Li S, Song Y et al. The biological effect of dentin noncollagenous proteins (DNCps) on the human periodontal ligament stem cells (HPDLScs) in vitro and in vivo. Tissue Eng Part A 2008; 14(12): 2059–2068.
9. Inoue T, Deporter DA, Melcher AH. Induction of chondrogenesis in muscle, skin, bone marrow, and periodontal ligament by demineralized dentin and bone matrix in vivo and in vitro. J Dent Res 1996; 65(1): 12–22.
10. Hoffman LM, Weston AD, Underhill TM. Molecular mechanisms regulating chondroblast differentiation. J Bone Joint Surg Am 2003; 85-A (Suppl 2): 124–132.
11 Lee JY, Nam H, Park YJ et al. The effects of platelet-rich plasma derived from human umbilical cord blood on the osteogenic differentiation of human dental stem cells. *In Vitro Cell Dev Biol Anim* 2011; **47**(2): 157–164.

12 Cho TJ, Kim JW, Kwon SK et al. A potent small-molecule inducer of chondrogenic differentiation of human bone marrow-derived mesenchymal stem cells. *Chem Sci* 2012; **3**: 3071–3075.

13 Sakaguchi Y, Sekiya I, Yagishita K et al. Suspended cells from trabecular bone by collagenase digestion become virtually identical to mesenchymal stem cells obtained from marrow aspirates. *Blood* 2006; **104**(9): 2728–2735.

14 Bruder SP, Horowitz MC, Mosca JD et al. Monoclonal antibodies reactive with human osteogenic cell surface antigens. *Bone* 1997; **21**(3): 225–235.

15 Craig W, Kay R, Cutler RL et al. Expression of Thy-1 on human hematopoietic progenitor cells. *J Exp Med* 1993; **177**(5): 1331–1342.

16 Tang QO, Shakib K, Heliotis M et al. TGF-beta3: a potential biological therapy for enhancing chondrogenesis. *Expert Opin Biol Ther* 2009; **9**(6): 689–701.

17 Estes BT, Wu AW, Guilak F. Potent induction of chondrocytic differentiation of human adipose-derived adult stem cells by bone morphogenetic protein 6. *Arthritis Rheum* 2006; **54**(4): 1222–1232.

18 Quintana L, zur Nieden NI, Semino CE. Morphogenetic and regulatory mechanisms during developmental chondrogenesis: new paradigms for cartilage tissue engineering. *Tissue Eng Part B Rev* 2009; **15**(1): 29–41.

19 Akiyama H, Chaboissier MC, Martin JF et al. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. *Genes Dev* 2002; **16**(21): 2813–2828.

20 Healy C, Uwanogho D, Sharpe PT. Expression of the chicken Sox9 gene marks the onset of cartilage differentiation. *Ann N Y Acad Sci* 1996; **785**: 261–262.

21 Wright E, Hargrave MR, Christiansen J et al. The Sry-related gene Sox9 is expressed during chondrogenesis in mouse embryos. *Nat Genet* 1995; **9**(1): 15–20.

22 DeLise AM, Fischer L, Tuan RS. Cellular interactions and signaling in cartilage development. *Osteoarthr Cartil* 2000; **8**(5): 309–334.

23 Kawakami Y, Rodriguez-Leon J, Izpisua Belmonte JC. The role of TGFbetas and Sox9 during limb chondrogenesis. *Curr Opin Cell Biol* 2006; **18**(6): 723–729.

24 Zhang G, Eames BF, Cohn MJ. Chapter 2. Evolution of vertebrate cartilage development. *Curr Top Dev Biol* 2009; **86**: 15–42. doi: 10.1016/s0070-2153(09)01002-3.

25 Doerge KJ, Sasaki M, Kimura T et al. Complete coding sequence and deduced primary structure of the human cartilage large aggregating proteoglycan, aggrecan. Human-specific repeats, and additional alternatively spliced forms. *J Biol Chem* 1991; **266**(2): 894–902.

26 Schwartz NB, Pirok EW 3rd, Mensch JR Jr et al. Domain organization, genomic structure, evolution, and regulation of expression of the aggrecan gene family. *Prog Nucleic acid Res Mol Biol* 1999; **62**: 177–225.

27 Rosa V, Della Bona A, Cavalcanti BN et al. Tissue engineering: from research to dental clinics. *Dent Mater* 2012; **28**(4): 341–348.

28 Yen AH, Yelick PC. Dental tissue regeneration—a mini-review. *Gerontology* 2011; **57**(1): 85–94.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0